Posted by Michael Wonder on 03 Sep 2024
Caribou Biosciences announces the FDA has granted fast track designations to CB-010 in refractory SLE and to CB-012 in relapsed or refractory AML
3 September 2024 - Additional FDA designation for CB-010 following earlier RMAT and fast track designations in B-NHL.
Caribou Biosciences today announced that the US FDA granted fast track designations to CB-010 for refractory systemic lupus erythematosus and to CB-012 for relapsed or refractory acute myeloid leukaemia.
